Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）胃肠手术等均影响药的生度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的生体内评价,解决药透过血脑屏障和生度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）或既往胃肠手术等均影响药的用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的体内评价,解决药透过血脑屏障和用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）或既往胃肠手术等影响药物的生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的生物体内评价,解决药物透过血脑屏障和生物利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良）或既往胃肠手术等均影响药物的生物利用。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

以后的工作重点是进行系统深入的生物体内评价,解决药物透过血脑屏障和生物利用等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）或既往胃肠手术等均影响的生利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的生体内评价,解决透过血脑屏障和生利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）或既往胃肠手术等均影响药物的生物利。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的生物体内评价,解决药物透过血脑生物利等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,不良综合征）或既往胃肠手术等均影响药物的生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出后的工作重点是进行系统深入的生物体内评价,解决药物透过血脑屏障和生物利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、、动情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）或既往胃肠手术等均影响药物的生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的生物体内评,药物透过血脑屏障和生物利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,不良综合征）既往胃肠手术等均影响药物的生物利用度。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出后的工作重点是进行系统深入的生物体内评价,解决药物透过血脑屏障和生物利用度等问题。

Age, sex, activity, genetic phenotype, stress, disease (eg, achlorhydria, malabsorption syndromes), or previous GI surgery can affect drug bioavailability.

年龄、性别、活动情况、遗传表型、应激、疾病（如胃酸缺乏,营养不良综合征）或既往胃肠手术均影响物的生物利。

The transportability through BBB and bioavailability of the inhibitors will be the focus by the systemafic bioassay in vivo.

指出以后的工作重点是进行系统深入的生物体内评价,解决物透过血脑屏障和生物利问题。